SE
63
2
BMY
58
-2
V
76
10
NWS
64
2
TAP
61
3
KSS
46
12
MPC
42
-2
SYF
88
3
DGX
44
-6
PM
64
2
NSC
65
5
CCI
33
2
USB
57
2
CRM
65
-2
PG
60
4
SRE
54
-12
AVGO
27
5
SWKS
55
5
DE
68
5
ECL
59
5
SE
63
2
BMY
58
-2
V
76
10
NWS
64
2
TAP
61
3
KSS
46
12
MPC
42
-2
SYF
88
3
DGX
44
-6
PM
64
2
NSC
65
5
CCI
33
2
USB
57
2
CRM
65
-2
PG
60
4
SRE
54
-12
AVGO
27
5
SWKS
55
5
DE
68
5
ECL
59
5
Financhill
Back

Fulcrum Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
50

FULC
Fulcrum Therapeutics

Last Price:
3.56
Seasonality Move:
57.36%

7 Day Trial

ALL ACCESS PASS

$ 7

Say this - unlock as much as $1,250 every Friday

Click here for full details.

Fulcrum Therapeutics Price Quote

$3.56
+0.12 (+3.49%)
(Updated: November 26, 2024 at 5:55 PM ET)

Fulcrum Therapeutics Key Stats

Sell
50
Fulcrum Therapeutics (FULC) is a Sell
Day range:
$3.24 - $3.56
52-week range:
$2.86 - $13.70
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0.72%
Volume:
957.7K
Avg. volume:
786K
1-year change:
-28.03%
Market cap:
$185.5M
Revenue:
$2.8M
EPS:
$-0.31

How Much Does Fulcrum Therapeutics Make?

Data Unavailable

Is Fulcrum Therapeutics Growing As A Company?

Data Unavailable

Fulcrum Therapeutics Stock Price Performance

What Is Fulcrum Therapeutics 52-Week High & Low?

Fulcrum Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Fulcrum Therapeutics?

Is Fulcrum Therapeutics Cash Flow Positive?

  • What Is FULC Cash Flow From Operations?
    Cash flow from operations (TTM) is -$8.6M
  • What Is Fulcrum Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $3M
  • What Is Fulcrum Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $48.3M

Fulcrum Therapeutics Return On Invested Capital

Data Unavailable

Fulcrum Therapeutics Earnings Date & Stock Price

Fulcrum Therapeutics Competitors

Fulcrum Therapeutics Dividend Yield

Fulcrum Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -16.55%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 5
Sell Recommendations: 0
Price Target: 5.29
Upside from Last Price: 53.65%

Major Shareholders

  • How many FULC shares are owned by institutional investors?
    115.6M FULC shares are owned by institutional investors
  • How many FULC shares are owned by insiders?
    1.1M FULC shares are owned by insiders